Amneal Pharmaceuticals reports that it has received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application of bimatoprost ophthalmic solution 0.01%. The therapy is a generic equivalent to Allergan/AbbVie's Lumigan (bimatoprost ophthalmic solution 0.01%), indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

According to IQVIA, US annual sales of bimatoprost ophthalmic solution 0.01% reached approximately $685 million for the 12 months ending July 2025, suggesting a sizable market for the generic entrant. Amneal's prostaglandin analog will be available in 2.5 mL, 5 mL, and 7.5 mL bottles.